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Antipsychotic-induced movement disorders are major side effects of antipsychotic drugs
among schizophrenia patients, and include antipsychotic-induced parkinsonism (AIP) and
tardive dyskinesia (TD). Substantial pharmacogenetic work has been done in this field,
and several susceptibility variants have been suggested. In this paper, the genetics of
antipsychotic-induced movement disorders is considered in a broader context. We hypoth-
esize that genetic variants that are risk factors for AIP andTD may provide insights into the
pathophysiology of motor symptoms in Parkinson’s disease (PD). Since loss of dopaminer-
gic stimulation (albeit pharmacological in AIP and degenerative in PD) is shared by the two
clinical entities, genes associated with susceptibility to AIP may be modifier genes that
influence clinical expression of PD motor sub-phenotypes, such as age at onset, disease
severity, or rate of progression. This is due to their possible functional influence on com-
pensatory mechanisms for striatal dopamine loss. Better compensatory potential might be
beneficial at the early and later stages of the PD course. AIP vulnerability variants could
also be related to latent impairment in the nigrostriatal pathway, affecting its functional-
ity, and leading to subclinical dopaminergic deficits in the striatum. Susceptibility of PD
patients to early development of L-DOPA induced dyskinesia (LID) is an additional relevant
sub-phenotype. LID might share a common genetic background with TD, with which it
shares clinical features. Genetic risk variants may predispose to both phenotypes, exerting
a pleiotropic effect. According to this hypothesis, elucidating the genetics of antipsychotic-
induced movement disorders may advance our understanding of multiple aspects of PD
and it clinical course, rendering this a potentially rewarding field of study.
Keywords: Parkinson’s disease, schizophrenia, antipsychotic-induced parkinsonism, tardive dyskinesia, L-DOPA
induced dyskinesia
INTRODUCTION
Since their introduction during the 1950s, antipsychotic drugs
have been the cornerstone of pharmacological treatment for schiz-
ophrenia and other psychotic disorders (1, 2). Although all effec-
tive antipsychotics are dopamine D2 receptor antagonists (3),
they are divided into two large categories, with different recep-
tor binding and side-effect profiles: first and second generation
antipsychotics (FGA, SGA) (4, 5).
Antipsychotic drugs are linked to a wide spectrum of adverse
effects. FGAs cause antipsychotic-induced movement disorders,
which are the focus of this paper. Antipsychotic-induced move-
ment disorders include acute manifestations (dystonia, parkinson-
ism, and akathisia) as well as long-lasting effects [tardive dyskinesia
(TD) and tardive dystonia] (2, 4). SGAs are linked to cardiometa-
bolic effects (6), although movement disorder rates among SGA
treated patients are not negligible and represent a prevalent
clinical challenge. In the vast psychiatric literature, the term
“antipsychotic-induced extrapyramidal symptoms (EPS)” is used
when referring to antipsychotic-induced movement disorders.
Although the meaning is the same, in this paper, we will refer
to “movement disorders” instead of EPS (which is considered
obsolete).
Extensive pharmacogenetic research has been performed in
the field of antipsychotics (7), implementing a candidate gene
approach and genome-wide association studies (GWASs) (8,
9). Regarding antipsychotic-induced movement disorders, most
pharmacogenetic work has focused on TD, with modest success.
Reviewing the literature of TD genetics is beyond the scope of
this paper; the reader is referred to a comprehensive review by Lee
and Kang (10). Briefly, candidate gene studies pointed to potential
involvement of genetic variants related to dopaminergic or sero-
tonergic transmission, drug metabolism (CYP enzyme family),
and oxidative stress mechanisms (10). Several TD–GWASs have
been performed, reporting some promising signals (11–14). Of
particular interest is the association of the HSPG2 SNP rs2445142
with TD, in Japanese and Caucasian populations (12, 15).
Genetic research on other types of antipsychotic-induced
movement disorders is limited. Moreover, many studies regard
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different forms of acute drug-induced movement disorders as a
single clinical entity (16). Studies that focus specifically on phar-
macogenetics of antipsychotic-induced parkinsonism (AIP) are
few, and have mostly concentrated on functional variants within
selected candidate genes such as the dopamine receptors DRD2
and DRD3 and serotonin receptors HTR2A and HTR2C (16, 17).
The Regulator of G protein signaling 2 (RGS2) gene was associated
with AIP (18, 19) and supported functionally by behavioral studies
of AIP like features in mice carrying a mutation leading to reduc-
tion of gene expression (20). However, other groups have failed
to validate this association. (21–23). An AIP-GWAS (24) revealed
association of the rs12678719 SNP in the ZFPM2 gene with this
phenotype, that was validated in an independent sample (25).
While pharmacogenetics may have major clinical value to per-
sonalized medicine in psychiatry (26, 27), the aim of this hypothe-
sis article is to put the genetics of antipsychotic-induced movement
disorders in a broader context. We suggest that genetic variants,
which are risk factors for AIP and TD, may provide insights into
a different disease related to the dopaminergic system, Parkin-
son’s disease (PD). This original hypothesis suggests that the same
genes, which confer susceptibility to or protection against AIP and
TD (among schizophrenia patients treated with antipsychotics),
may be modifier genes that influence the clinical expression of PD
in those affected by this disease. AIP variants might be related to
compensatory mechanisms for dopamine loss in the striatum, or
influence nigrostriatal (NS) pathway integrity and functionality
and thereby possibly modulate PD motor sub-phenotypes such as
age at disease onset and rate of disease progression. Another sub-
phenotype of importance is susceptibility of PD patients to early
development of a serious side effect of dopaminergic treatment,
l-DOPA induced dyskinesia (LID). LID may share a common
genetic background with TD, with which it shares clinical features.
In the following sections, we present epidemiological, imaging,
and molecular data that support this line of thought. Naturally, we
do not claim that AIP and motor symptoms of PD or TD and LID
are clinically identical entities. On the other hand, there is substan-
tial and intriguing similarity between two phenotype pairs, which
is the background to our hypothesis. Although the empirical sup-
porting evidence for our assumptions is limited at the current
stage of the field (as presented below) and some of the underly-
ing assumptions might be eventually wrong, the aim of this paper
is to introduce a novel hypothesis and perspective, challenging
future study in this direction (employing more advanced genetic,
genomic, and epigenetic tools), rather than to reach definitive
conclusions.
AIP IN RELATION TO PD GENETICS
ANTIPSYCHOTIC-INDUCED PARKINSONISM
Antipsychotic-induced parkinsonism, the most common man-
ifestation of antipsychotic-induced movement disorders, is an
acute, reversible side effect (28, 29). AIP prevalence varies widely
from 15% to more than 40% of patients treated with antipsy-
chotics (30, 31). This substantial heterogeneity may stem from
inter-study differences in medication regimens and patient demo-
graphic background. Well documented risk factors for AIP are
antipsychotic type (FGA versus SGA), high doses of antipsychotics,
old age, and female gender (32, 33). According to data from the
1960s, most affected patients develop AIP within the first 2 months
of antipsychotic exposure, or even earlier (34, 35). Improvement
occurs within a few months.
The pathophysiology of AIP is not entirely clear. As a dose
dependent phenomenon, it involves occupancy of the NS pathway
dopamine D2 receptor (DRD2s) (36). All known, antipsychotics
are DRD2s blockers and are thought to reduce psychotic symptoms
by blocking these receptors in the mesolimbic dopamine pathway
(4). An undesired effect is blockade of DRD2s in the NS pathway.
Occupancy of more than 80% of DRD2s, as produced by typical
antipsychotics, significantly increases AIP risk, while occupancy
<70% induces no AIP (31). The reduced tendency of SGAs to
cause AIP may be related to their faster dissociation from DRD2s,
compared to FGAs (36).
Parkinson’s disease is a common neurodegenerative disorder,
characterized pathologically by selective loss of dopaminergic neu-
rons projecting from the substantia nigra to the striatum with con-
comitant reduction in the striatal concentration of dopamine and
accumulation of Lewy bodies (37). Disease manifestation includes
motor and non-motor symptoms, variable clinical expression, and
a slowly deteriorating course (38, 39). The central motor features
of PD are tremor at rest, rigidity, bradykinesia, postural instability,
flexed posture, and freezing of gait (40). Genetic variants con-
sidered risk factors for development of PD include common SNPs
[e.g., within MAPT and SNCA (41)] and rare variants (e.g., within
LRRK2 and GBA genes) (42, 43), but multiple environmental risk
factors were also reported (44).
The motor symptoms of AIP are similar to those of PD (45,
46). Indeed, there are clinical settings in which it is difficult to
distinguish between the two (45, 47). Although AIP is considered
to be more symmetric and less characterized by tremor compared
than PD (48, 49), asymmetry, and tremor do occur frequently AIP
patients (45, 50, 51). Other study suggested that AIP affects the
upper limbs more than the lower ones (50). Naturally, reversibility
of signs following antipsychotics withdrawal is characteristic of
AIP and not PD. When reversibility does not happen, one should
suspect underlying PD and consider DAT-SPECT examination
(see below) (47). Also, while AIP is essentially a motor side effects
among schizophrenia or other psychotic patients, the clinical pic-
ture of PD is much broader, and includes multiple non-motor
symptoms such as neuropsychiatric disturbances (for example
depression, anxiety, and hallucinations), cognitive decline, and
autonomic dysfunction (52).
We suggest that genes associated with susceptibility to AIP may
be modifier genes that influence the clinical expression of PD
motor symptoms. The hypothesis is tethered in the fact that loss of
dopaminergic stimulation (albeit reversible in AIP and irreversible
in PD) is a core feature of both clinical entities. Thus, genes that
affect occurrence and severity of AIP in schizophrenia patients
exposed to antipsychotic-induced loss of dopaminergic stimula-
tion, could have a similar role in modulating severity of several
clinical aspects among PD patients (with neurodegenerative loss
of dopaminergic NS input). Identification of gene variants that
are protective against AIP (caused by administration of dopamine
antagonist) could advance our understanding of the intrinsic abil-
ity of an individual to compensate for dopamine loss (best mani-
fested in the context of PD). In addition, AIP vulnerability variants
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may be associated with subclinical dopaminergic deficits in the
striatum that are aggravated by exposure to antipsychotics. There-
fore, these variants could provide clues to the genetic contribution
to NS pathway integrity in schizophrenia and PD.
AIP GENETIC VARIANTS AND COMPENSATORY MECHANISMS IN PD
Parkinsonian motor signs manifest only following degeneration
of 70–80% of the NS dopaminergic neuron population (53, 54).
Post-mortem analysis of Parkinsonian brains indicates that exten-
sive loss of dopamine in the putamen and caudate nucleus can
be accompanied by minor clinical manifestations only (55, 56).
Inter-individual difference in severity of motor symptoms during
early and mid-duration PD may be attributed to existence or lack
of compensatory mechanisms that counterbalance dopamine loss
(57), and reduce severity of motor symptoms and progression rate
(58). Several categories of potential compensatory mechanisms
(in the striatum, basal ganglia, and cortical/cerebellar) have been
recognized in PD [reviewed in Ref. (58, 59) and summarized in
Table 1].
If extrapolation is made from these putative compensatory
mechanisms in PD to schizophrenia patients exposed to antipsy-
chotics, lower severity of AIP symptoms seems related to the ability
of the individual to counterbalance lack of dopamine induced by
exogenous block of dopaminergic transmission. Individuals with
Table 1 | Examples for compensatory mechanisms categories in PD.
(A) Striatum localized mechanisms that maximize the
effect of the remaining dopamine in this region, pre- and
post-synaptic
1. Upregulation of enzymes involved in dopamine
metabolism [such as tyrosine hydroxylase (TH) or aromatic
acid decarboxylase (AADC)] in order to increase dopamine
synthesis in the residual neurons
(60–62)
2. Upregulation of DRD2 expression on striatal neurons
(augmenting responsiveness to the remaining dopamine)
(63–65)
3. Downregulation of the dopamine transporter (DAT), which
leads to decreased dopamine reuptake and higher
concentration in the synaptic cleft
(62, 66, 67)
4. Increase in the number of intrinsic striatal tyrosine
hydroxylase (TH) interneurons
(68–70)
(B) Compensatory mechanisms located outside the
striatum, and linked to modulation of basal ganglia
direct and indirect pathways
Reduction of globus pallidus externa inhibition by the
indirect pathway, reducing PD symptom severity. This might
be mediated by several neurotransmitter systems, which
reduce activity of the indirect pathway (for example,
enkephalins)
(58, 71)
(C) Compensatory mechanisms positioned in brain
regions and networks outside the basal ganglia but
involved in motor system control
Increased activity of relevant cortical (e.g., supplementary
motor area) and cerebellar regions (counterbalancing
impaired basal ganglia function)
(72–74)
higher compensatory potential would be less likely to develop AIP
when treated with antipsychotics, due to mechanisms found at
both striatal and extra-striatal levels, as mentioned above. Inter-
personal differences in compensatory ability could be explained,
at least partially, by genetic variants that are linked to one or
more of the compensatory mechanisms,described in PD. However,
PD pathophysiology involves loss of all dopaminergic transmis-
sion (both D1 and D2 receptor pathways), while AIP is primarily
related to blockade of the DRD2 pathway. Therefore, the relevant
compensatory mechanisms that effect AIP severity are probably
more specifically related to DRD2 signaling at the striatal level,
but may be more general and essentially similar to those mecha-
nisms involved in PD at the extra-striatal level (e.g., alternation of
indirect pathway activity by involvement of additional neurotrans-
mission systems, or recruitment of brain region and networks in
motor regions in the cortex or in the cerebellum that modulate
parkinsonian symptoms and produce compensatory effect – as
presented in Table 1).
If taken one step further, AIP genetic variants could be rele-
vant for etiology of some sub-phenotypes of PD motor symp-
toms, resulting in early or delayed disease onset, or accelerated or
retarded rate of progression. PD is a late-onset disease, and the
mean age at onset (AAO) is approximately 60 years (75). How-
ever, AAO of the disease is variable, ranging from early onset cases
to cases in the 8th–9th decades of life (76, 77), and several genes
have been associated with PD AAO (75, 78, 79). Identification of
AIP protective variants can advance understanding of the intrin-
sic ability of an individual to compensate for dopamine loss and
delay appearance of clinical PD motor symptoms. More specifi-
cally, we suggest that AIP susceptibility variants may be associated
with earlier AAO among PD patients (lower ability to compensate
for dopamine loss) and AIP protective variants with delayed AAO
of motor symptoms (better compensatory capacity).
In a small pilot study (Greenbaum et al., unpublished), we
checked this hypothesis by genotyping several top AIP variants,
and analyzing their association with PD AAO [SNPs were chosen
from our AIP–GWAS and previous RGS2 papers (18, 19, 24)]. We
used two independent PD samples, recruited in Italy (N = 703,
age range 34–76) and Israel (N = 233, age range 37–81). Two
nominally significant associations in the expected direction were
observed in the Italian sample, but did not withstand correction
for multiple testing and were not validated in the Israeli sam-
ple. The negative findings do not necessarily mean that our basic
assumption is incorrect. The fact that we were unable to support
our hypothesis in this pilot study may stem from the relatively
small sample sizes and limited statistical power. Alternatively, some
of the AIP variants selected for this investigation may be false-
positive due to spurious results in previous studies. If robust AIP
risk variants are still undiscovered, lack of association with this PD
sub-phenotype is understandable.
SUBCLINICAL DOPAMINERGIC DEFICITS IN THE NS AND AIP RISK
VARIANTS
Turning back to schizophrenia patients, an alternative functional
explanation for the role of AIP genetic risk variants may be
their influence on NS pathway integrity (and therefore its abil-
ity to deliver sufficient amount of dopamine to the striatum).
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Dopaminergic deficits in the NS pathway may thus be a predispos-
ing factor for AIP since schizophrenia patients with latent subclin-
ical deficits in NS function would be more susceptible to external
blockade of dopaminergic receptor, as happens in AIP (double hit
model: underlying dopamine NS defect exaggerates DRD2 block-
ade). Thus, among AIP patients carrying the risk allele, adminis-
tration of antipsychotic drugs that block DRD2s might aggravate
preexisting, subclinical, pre-synaptic dopaminergic changes.
Integrity of NS tract can be evaluated by neuroimaging meth-
ods, including [123I]FP-CIT SPECT. The cocaine derivate [123I]-
FP-CIT is a sensitive marker for degeneration of the NS pathway,
due to its binding to the dopamine transporter (DAT), a pro-
tein localized to pre-synaptic dopaminergic terminals (80, 81). By
implementing this neuroimaging technique to quantify dopamin-
ergic deficits, it is possible to study the effects of AIP risk variants
on NS integrity among healthy individuals and PD or schizo-
phrenia patients and thereby link genetic variants to pre-synaptic
dopaminergic changes. There is evidence that 33–44% of variabil-
ity in pre-synaptic dopamine uptake in the striatum is influenced
by genetic factors (82).
We previously examined the hypothesis that AIP risk alleles
would be associated with lower FP-CIT uptake in the putamen
and caudate. In a small sample of early stage, Israeli, PD patients
(N = 49), we genotyped and analyzed the association of the
ZFPM2 rs12678719 AIP risk variant (discovered in our AIP–GWAS
and validated in an additional population) with degree of NS path-
way terminal degeneration, as evaluated by DAT-SPECT (25). We
found that the AIP risk allele “G” was significantly associated with
lower ligand uptake in the contralateral putamen (contralateral to
the worst body side of parkinsonism), when controlling for disease
duration (25). This implies that at least among PD patients, this
variant may be linked to mechanisms that increase dopaminergic
deficits in the NS pathway, a potential predisposing factor for AIP
among schizophrenia patients. Interestingly, several neuroimaging
studies in drug-induced parkinsonism patients showed that some
of them manifest significantly diminished striatal binding in DAT
scans (47, 83–85). For example, abnormal SPECT findings were
found in 41 of 97 AIP affected schizophrenia patients (42%) in
a recent study, raising the possibility of coexistence of NS defects
combined with DRD2 blockade by antipsychotics (49). Accord-
ing to our hypothesis, this finding might be explained by genetic
factors predisposing to the subclinical NS deficits.
Taken together, it is possible that AIP associated variants will
provide insights into genetic factors influencing dopamine secre-
tion capacity, related to NS integrity and function. This informa-
tion may be valuable for understanding the preclinical stages of
PD in which substantial NS degeneration exist, despite few clinical
motor manifestations. Combination of existing subclinical deficits
at baseline state, with ongoing neurodegenerative disease, could
result in earlier AAO and faster disease progression rate.
POSSIBLE COMMON GENETIC RISK FACTORS FOR TD
AND LID
TD AND LID
Tardive dyskinesia is a chronic, severe, and potentially irreversible
adverse effect of prolonged exposure to antipsychotics (36, 86). TD
is characterized by abnormal involuntary movements of the face
and extremities, and may fluctuate in severity (86, 87). In patients
treated with FGAs, the incidence of TD is estimated as 5% per
year (88), with a prevalence range of 20–25% among schizophre-
nia patients treated with antipsychotics chronically (86). SGAs are
considered less likely to cause TD than FGAs, approximately 1%
annually (89), but this rate is higher, according to other reports
(90). Risk factors for TD include older age, female gender, and
duration and intensity of antipsychotic treatment (91, 92). Genetic
predisposition probably plays a role in determining individual TD
susceptibility, as described in the introduction.
The etiology of TD is unknown, and several explanations
have been suggested including supersensitivity of post-synaptic
dopamine D2 receptors in the NS pathway following long-lasting
blockade of dopamine (93, 94). Other possible mechanisms are
damage to striatal GABA-containing neurons and dysregulation of
this system (95), degeneration of striatal cholinergic interneurons
(87), or neuronal damage (neurotoxicity) due to overproduction
of free radicals (96, 97). Interestingly, there is evidence that sponta-
neous dyskinesia, similar to TD,may be present among schizophre-
nia patients who are antipsychotic naïve, therefore related to the
disease itself (98, 99), and the prevalence increases with advancing
age (100).If true, it could be that antipsychotics exposure exac-
erbates the manifestation of an intrinsic “motor component” of
schizophrenia, which is not merely a side effect of drugs (101).
TD susceptibility genes may therefore represent risk variants for
a “motor prone subtype” of schizophrenia (and manifests only
among minority of patients), which is related to schizophrenia
pathophysiology itself, rather than pure results of drug exposure.
Moving again to PD, dopamine replacement therapy [in par-
ticular, levodopa (l-DOPA)], is regarded as the pharmacological
therapy of choice for the motor symptoms of this disease (37,
40). The majority of PD patients respond well to l-DOPA dur-
ing the early years of treatment (102), but most will ultimately
experience disabling adverse motor manifestations such as motor
fluctuations and LID. LID is involuntary movements, mostly chor-
eiform or dystonic in nature, affecting discrete body parts (103).
Once established, LID is irreversible and appears on every admin-
istration of the dopaminergic agent (104). Several classifications
for LID have been purposed; the most common types are peak-
dose and diphasic (105). Although the overwhelming majority of
PD patients will eventually develop LID (approximately 90% after
15 years of drug exposure) (106–108), some individuals develop it
early and others relatively late. An accepted estimate is that approx-
imately 40% of PD patients will develop LID following 4–6 years of
l-DOPA treatment (109). Inter-individual differences in LID sus-
ceptibility and onset-time may be explained by a combination of
demographic, clinical, and genetic risk factors. Higher LID vulner-
ability is linked to younger age at PD onset, longer PD duration,
longer duration of l-DOPA treatment, higher drug doses, and
female gender (103, 110). Genetic factors may contribute to LID
variability in combination with clinical risk factors.
The underlying etiology of LID is unclear. LID development
first requires denervation of the basal ganglia (as happens in
PD), which changes response to future dopaminergic medica-
tions (105). Then, chronic consumption of l-DOPA (or other
dopaminergic agents) causes pulsatile and non-physiological stim-
ulation of dopamine receptors in the striatum. The result is
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disturbance in anatomical pathways and functional mechanisms,
which are responsible for proper motor control (104). This may
be mediated by aberrant neuroplasticity and remodeling of rel-
evant neuronal connectivity (104, 111). D1 receptors and their
downstream signaling cascade are considered to contribute sub-
stantially to LID pathophysiology (112), although other receptors
are probably also relevant [e.g., DRD3, GABA-A, adenosine A2A,
and more (104, 112)].
l-DOPA induced dyskinesia and TD are both phenotypes of
drug-induced hyperkinetic movement disorders, which share clin-
ical similarities and may have an intersecting genetic background,
as discussed below. Nevertheless, there are also some prominent
clinical features, which differentiate the two types of dyskinesia.
TD is more characterized by oral, buccal, and lingual movements
(which are repetitive and complex), and limbs and trunk involve-
ment is less severe (113). Compared to TD, LID is phenomenologi-
cally more heterogeneous, and includes chorea, athetosis, dystonia,
and myoclonus (103, 114). Also, LID is pronounced in the extrem-
ities and neck (115, 116), and tend to start on the body side more
severely affected by PD (113). Epidemiologically, two important
and interrelated risk factors for LID susceptibility are younger age
at PD onset and longer disease duration (117–119), while the most
consistently established risk factor for TD is advancing age (120,
121). These differences should be kept in mind.
TD AND LID: INTERSECTION OF THEIR GENETIC BACKGROUND
Based on the clinical and the neurobiological similarities of the
two chronic drug-induced dyskinesia phenomena, we suggest a
possible common genetic background shared by TD and LID,
such that particular genetic variants are associated with suscep-
tibility to TD as well as LID (same risk allele). Although the
underlying disease context is different, there is a high level of
clinical similarity between TD to LID, both being hyperkinetic
phenotypes with uncontrolled movements. The two disorders are
associated with an imbalance in the dopamine system, due to years
of drug treatment leading to chronic, non-physiological, pulsatile
stimulation (LID), or blockade (TD) of dopaminergic receptors.
Analogy between two phenotypes may also be found at the phar-
macological level; for example, overactivity of the glutamatergic
system (104, 122). Amantadine, a glutamatergic antagonist, sup-
presses LID (123, 124) and also improves TD among schizophrenia
patients (99, 125). Using MRI, volumetric abnormalities in the
inferior frontal gyrus were demonstrated in patients with both
phenotypes (126, 127).
Thus, we hypothesize that factors important in the pathophys-
iology of TD might be insightful for understanding that of LID
(104). Actually, the potential existence of similar pathophysiolog-
ical mechanisms between LID and TD is not new in the literature,
and was postulated previously by several authors (104, 128, 129).
The emphasis on the genetic aspect of this hypothesis is the nov-
elty of this manuscript. Besides contributing to the molecular
understanding of both TD and LID per se, this insight (if cor-
rect) may advance the field of PD pharmacogenetic as well as that
of schizophrenia, due to reciprocal influences. Common genetic
variants may predispose to both phenotypes. According to this
risk allele sharing notion, risk variants for TD (among schizo-
phrenia patients) may be relevant to early LID susceptibility in PD
affected individuals, representing a pleiotropic effect. The extent
of this genetic overlap is probably limited and partial, while addi-
tional genetic risk variants confer susceptibility to LID or TD,
separately.
In a proof of concept study, we analyzed the association of 21
TD-associated SNPs with LID susceptibility in two independent
samples of PD patients (130). SNPs were chosen based on pre-
vious TD–GWASs in several populations (12–14) and top results
from the candidate gene literature. Controlling for relevant clini-
cal variables, only a single SNP (DRD2 rs1800497) was associated
with LID in the Italian sample (187 early LID developers versus
203 non-early developers), in the expected direction of effect. This
finding was not validated in a Jewish Israeli sample (128 LID pos-
itive and 75 negative, after 3 years of drug exposure), and did not
withstand correction for multiple testing (130). However, the neg-
ative findings do not exclude the possible validity of our initial
hypotheses of shared genetic predisposition (alternative explana-
tions to lack of confirmation are elaborated above, in Section “AIP
Genetic Variants and Compensatory Mechanisms in PD”). The
goal of our preliminary data presentation was to demonstrate the
applicability of this approach, and its possible implementation.
Compared to the relatively extensive volume of pharmacoge-
netic studies in TD, research on the genetics of LID is limited.
Several candidate gene studies were performed in small samples
[for example, Ref. (131–133)], but results are mostly inconsistent
and lack replications. GWASs have not been published for LID thus
far. Findings from the more mature field of TD genetics may pro-
vide reasonable candidate genetic variants for LID research (and
if validated also molecular targets for further research and drug
development). Analysis of novel and robust TD variants detected
in the future for association with LID is indicated and may sup-
port our hypothesis. Moreover, when LID GWASs are hopefully
performed and published in the future, it will be of interest to com-
pare the top association signals from GWASs of both phenotypes,
looking for overlapping risk variants and genes.
CONCLUSION
Further application of pharmacogenetic tools to antipsychotic
drug therapy is greatly needed (134, 135). Identification of genetic
biomarkers that may assist in a priori prediction of antipsychotic-
induced movement disorders manifestations such as AIP and TD
among schizophrenia patients will be of great value. The aim of
this article has been to broaden the context of antipsychotic-
induced movement disorders genetics research. We put forward
the hypothesis that extending our understanding of the genetic
background of AIP and TD and applying this knowledge to PD
could render pivotal insights into genetic and molecular aspects of
PD, provide new targets for drug development, and assist in finding
biomarkers for personalized medicine. We have suggested that:
- Genes, which confer susceptibility to or protection against
antipsychotic-induced movement disorders (in particular, AIP
and TD), might also be modifier genes that influence PD motor
clinical features.
- AIP linked variants may shed light on PD sub-phenotypes
such as AAO or rate of disease progression, due to their pos-
sible functional influence on compensatory mechanisms for
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dopamine loss in the striatum, and/or to latent deficits of the
NS pathway.
- TD and LID may share genetic risk variants, associated with
an uncontrolled hyperkinetic phenotype that appears follow-
ing long-term fluctuating and non-physiological stimulation of
striatal dopaminergic receptors.
As an unproven hypothesis, not well supported by empirical
data, caution in evaluation is required. We render only modest
empirical support for our hypothesis, based on traditional phar-
macogenetics association studies (candidate genes and GWASs),
in relatively small and probably underpowered samples. However,
the aim of this paper is to raise new postulations, and stimulate
direction for future research. Due to recent advances in last decade
in genetics, genomics, and epigenetics research, we are now in a
better position that may enable systematic investigation of these
hypotheses in detail, beyond the limited tools used to date.
Larger sample GWASs will assist in this task, especially when
combined with a pathway analysis approach. Since phenotype
susceptibility depend on cumulative effect of variants within mul-
tiple genes in relatively small number of functional pathways
(136, 137), this method may assist in shedding light on shared
molecular pathways between phenotypes of interest, beyond the
contribution of specific gene. Also, beneficial is the employ-
ment of functional genomics methods, which detect alternation
in expression profile at the transcriptome and proteomic level,
where large number of genes/proteins are analyzed simultaneously
(135, 136, 138). Peripheral white blood cells and post-mortem
brain tissue are potential tissue sources to discover genomic bio-
markers correlated to AIP, TD, and LID. The same sources shall
also be used in investigation of shared epigenetics mechanisms
to phenotypes of interest, such as DNA methylation or micro
RNA (e.g., epigenome-wide association studies) (43, 139). Last,
multiple rare genetic variants with large effect size (discovery
by whole exome sequencing) may also be relevant to genet-
ics of antipsychotic-induced movement disorders, and its inter-
section with PD. Currently, understanding the contribution of
rare variants to pharmacogenetic traits is only at the beginning.
Integration of data derived from these approaches, in addition
to animal models studies (available for most phenotypes dis-
cussed here), aiming to gain mechanistic insights – will assist
in better understanding of the genetic architecture of the phe-
notypes discussed above, and the potential intersection between
them.
As novel findings and mechanisms will emerge and accumu-
late, it will be possible to validate the hypothesis presented, or
refute it. However, if these assumptions are correct, even partially,
then the incentive for deciphering antipsychotic-induced move-
ment disorders genetic is high, with broader applications for PD
and schizophrenia research.
AUTHOR CONTRIBUTIONS
LG and BL jointly developed the concept of this article, reviewed
the relevant literature, and wrote the manuscript.
ACKNOWLEDGMENTS
Supported in part by a Rapid Response Innovation grant from the
Michael J. Fox Foundation for Parkinson’s Research.
REFERENCES
1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO,
et al. Effectiveness of antipsychotic drugs in patients with chronic schizophre-
nia. N Engl J Med (2005) 353(12):1209–23. doi:10.1056/NEJMoa051688
2. Stahl SM. Stahl’s Essential Psychopharmacology Neuroscientific Basis and Prac-
tical Applications. 3rd ed. New York: Cambridge university press (2008).
3. Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsy-
chotics in patients with schizophrenia. CNS Drugs (2011) 25(11):933–69.
doi:10.2165/11595380-000000000-00000
4. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophre-
nia: a critical review of pharmacology and mechanisms of action of antipsy-
chotic drugs. Mol Psychiatry (2005) 10(1):79–104. doi:10.1038/sj.mp.4001556
5. Ellenbroek BA. Psychopharmacological treatment of schizophrenia: what do
we have, and what could we get? Neuropharmacology (2012) 62(3):1371–80.
doi:10.1016/j.neuropharm.2011.03.013
6. Fenton WS, Chavez MR. Medication-induced weight gain and dyslipidemia
in patients with schizophrenia. Am J Psychiatry (2006) 163(10):1697–704.
doi:10.1176/ajp.2006.163.10.1697
7. Cacabelos R, Hashimoto R, Takeda M. Pharmacogenomics of antipsychotics
efficacy for schizophrenia. Psychiatry Clin Neurosci (2011) 65(1):3–19. doi:10.
1111/j.1440-1819.2010.02168.x
8. Chowdhury NI, Remington G, Kennedy JL. Genetics of antipsychotic-induced
side effects and agranulocytosis. Curr Psychiatry Rep (2011) 13(2):156–65.
doi:10.1007/s11920-011-0185-3
9. Muller DJ, Chowdhury NI, Zai CC. The pharmacogenetics of antipsychotic-
induced adverse events. Curr Opin Psychiatry (2013) 26(2):144–50. doi:10.
1097/YCO.0b013e32835dc9da
10. Lee HJ, Kang SG. Genetics of tardive dyskinesia. Int Rev Neurobiol (2011)
98:231–64. doi:10.1016/B978-0-12-381328-2.00010-9
11. Aberg K, Adkins DE, Bukszar J, Webb BT, Caroff SN, Miller DD,
et al. Genomewide association study of movement-related adverse antipsy-
chotic effects. Biol Psychiatry (2010) 67(3):279–82. doi:10.1016/j.biopsych.
2009.08.036
12. Syu A, Ishiguro H, Inada T, Horiuchi Y, Tanaka S, Ishikawa M, et al. Association
of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsy-
chopharmacology (2010) 35(5):1155–64. doi:10.1038/npp.2009.220
13. Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B. Evidence for association of
the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia.
Mov Disord (2010) 25(16):2809–17. doi:10.1002/mds.23377
14. Tanaka S, Syu A, Ishiguro H, Inada T, Horiuchi Y, Ishikawa M, et al. DPP6 as a
candidate gene for neuroleptic-induced tardive dyskinesia. Pharmacogenomics
J (2013) 13(1):27–34. doi:10.1038/tpj.2011.36
15. Greenbaum L, Alkelai A, Zozulinsky P, Kohn Y, Lerer B. Support for associa-
tion of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacoge-
nomics J (2012) 12(6):513–20. doi:10.1038/tpj.2011.32
16. Al Hadithy AF, Wilffert B, Stewart RE, Looman NM, Bruggeman R, Brouw-
ers JR, et al. Pharmacogenetics of parkinsonism, rigidity, rest tremor, and
bradykinesia in African-Caribbean inpatients: differences in association with
dopamine and serotonin receptors. Am J Med Genet B Neuropsychiatr Genet
(2008) 147B(6):890–7. doi:10.1002/ajmg.b.30746
17. Gunes A, Dahl ML, Spina E, Scordo MG. Further evidence for the association
between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects
in male schizophrenic patients. Eur J Clin Pharmacol (2008) 64(5):477–82.
doi:10.1007/s00228-007-0450-x
18. Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O, et al. Asso-
ciation of the RGS2 gene with extrapyramidal symptoms induced by treatment
with antipsychotic medication. Pharmacogenet Genomics (2007) 17(7):519–28.
doi:10.1097/FPC.0b013e32800ffbb4
19. Greenbaum L, Smith RC, Rigbi A, Strous R, Teltsh O, Kanyas K, et al. Further
evidence for association of the RGS2 gene with antipsychotic-induced parkin-
sonism: protective role of a functional polymorphism in the 3’-untranslated
region. Pharmacogenomics J (2009) 9(2):103–10. doi:10.1038/tpj.2008.6
20. Greenbaum L, Lifschytz T, Zozulinsky P, Broner EC, Slonimsky A, Kohn Y, et al.
Alteration in RGS2 expression level is associated with changes in haloperidol
induced extrapyramidal features in a mutant mouse model. Eur Neuropsy-
chopharmacol (2012) 22(5):379–86. doi:10.1016/j.euroneuro.2011.09.006
21. Al Hadithy AF, Wilffert B, Bruggeman R, Stewart RE, Brouwers JR, Matroos
GE, et al. Lack of association between antipsychotic-induced parkinsonism or
its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the
Frontiers in Neurology | Movement Disorders February 2015 | Volume 6 | Article 27 | 6
Greenbaum and Lerer Antipsychotic-induced movement disorders and PD genetics
possible role of the medication: the Curacao extrapyramidal syndromes study
X. Hum Psychopharmacol (2009) 24(2):123–8. doi:10.1002/hup.997
22. Higa M, Ohnuma T, Maeshima H, Hatano T, Hanzawa R, Shibata N, et al.
Association analysis between functional polymorphism of the rs4606 SNP
in the RGS2 gene and antipsychotic-induced parkinsonism in Japanese
patients with schizophrenia: results from the Juntendo University Schizophre-
nia Projects (JUSP). Neurosci Lett (2010) 469(1):55–9. doi:10.1016/j.neulet.
2009.11.043
23. Bakker PR, Bakker E, Amin N, van Duijn CM, van Os J, van Harten PN. Can-
didate gene-based association study of antipsychotic-induced movement dis-
orders in long-stay psychiatric patients: a prospective study. PLoS One (2012)
7(5):e36561. doi:10.1371/journal.pone.0036561
24. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B. Genome-wide association
study of antipsychotic-induced parkinsonism severity among schizophrenia
patients. Psychopharmacology (Berl) (2009) 206(3):491–9. doi:10.1007/s00213-
009-1627-z
25. Greenbaum L, Smith RC, Lorberboym M, Alkelai A, Zozulinsky P, Lifschytz T,
et al. Association of the ZFPM2 gene with antipsychotic-induced parkinsonism
in schizophrenia patients. Psychopharmacology (Berl) (2012) 220(3):519–28.
doi:10.1007/s00213-011-2499-6
26. Lerer B, Segman RH. Pharmacogenetics of antipsychotic therapy: pivotal
research issues and the prospects for clinical implementation. Dialogues Clin
Neurosci (2006) 8(1):85–94.
27. Zhang JP, Malhotra AK. Pharmacogenetics of antipsychotics: recent progress
and methodological issues. Expert Opin Drug Metab Toxicol (2013)
9(2):183–91. doi:10.1517/17425255.2013.736964
28. Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, et al. Atypi-
cal antipsychotics and parkinsonism. Arch Intern Med (2005) 165(16):1882–8.
doi:10.1001/archinte.165.16.1882
29. Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyra-
midal symptoms predict later tardive dyskinesia: a prospective analysis of
10,000 patients in the European schizophrenia outpatient health outcomes
(SOHO) study. Am J Psychiatry (2006) 163(8):1438–40. doi:10.1176/appi.ajp.
163.8.1438
30. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull
(1997) 23(4):567–82. doi:10.1093/schbul/23.4.567
31. Hirose G. Drug induced parkinsonism: a review. J Neurol (2006) 253(Suppl
3):III/22–III/4.
32. Ebadi M, Srinivasan SK. Pathogenesis, prevention, and treatment of
neuroleptic-induced movement disorders. Pharmacol Rev (1995) 47(4):
575–604.
33. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced
by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol
Clin (2011) 29(1):127–48. doi:10.1016/j.ncl.2010.10.002
34. Ayd FJ Jr. A survey of drug-induced extrapyramidal reactions. JAMA (1961)
175:1054–60. doi:10.1001/jama.1961.03040120016004
35. Freyhan FA. Therapeutic implications of differential effects of new phenoth-
iazine compounds. Am J Psychiatry (1959) 115(7):577–85. doi:10.1176/ajp.
115.7.577
36. Casey DE. Pathophysiology of antipsychotic drug-induced movement disor-
ders. J Clin Psychiatry (2004) 65(Suppl 9):25–8.
37. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet (2009)
373(9680):2055–66. doi:10.1016/S0140-6736(09)60492-X
38. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron
(2003) 39(6):889–909. doi:10.1016/S0896-6273(03)00568-3
39. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez
M, et al. Missing pieces in the Parkinson’s disease puzzle. Nat Med (2010)
16(6):653–61. doi:10.1038/nm.2165
40. Fahn S. How do you treat motor complications in Parkinson’s disease: med-
icine, surgery, or both? Ann Neurol (2008) 64(Suppl 2):S56–64. doi:10.1002/
ana.21453
41. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harb
Perspect Med (2012) 2(1):a008888. doi:10.1101/cshperspect.a008888
42. Shulman JM, De Jager PL, Feany MB. Parkinson’s disease: genetics and patho-
genesis. Annu Rev Pathol (2011) 6:193–222. doi:10.1146/annurev-pathol-
011110-130242
43. Coppede F. Genetics and epigenetics of Parkinson’s disease. ScientificWorld-
Journal (2012) 2012:489830. doi:10.1100/2012/489830
44. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees
AJ, et al. Meta-analysis of early nonmotor features and risk factors for Parkin-
son disease. Ann Neurol (2012) 72(6):893–901. doi:10.1002/ana.23687
45. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical fea-
tures and results of treatment with levodopa. J Neurol Neurosurg Psychiatry
(1988) 51(6):850–4. doi:10.1136/jnnp.51.6.850
46. Susatia F, Fernandez HH. Drug-induced parkinsonism. Curr Treat Options
Neurol (2009) 11(3):162–9. doi:10.1007/s11940-009-0019-3
47. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R.
[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism
from Parkinson’s disease. Mov Disord (2006) 21(4):510–4. doi:10.1002/mds.
20748
48. Hausner RS. Neuroleptic-induced parkinsonism and Parkinson’s disease: dif-
ferential diagnosis and treatment. J Clin Psychiatry (1983) 44(1):13–6.
49. Tinazzi M, Cipriani A, Matinella A, Cannas A, Solla P, Nicoletti A, et al.
[(1)(2)(3)I]FP-CIT single photon emission computed tomography findings
in drug-induced parkinsonism. Schizophr Res (2012) 139(1–3):40–5. doi:10.
1016/j.schres.2012.06.003
50. Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, et al.
Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm
(2001) 108(11):1299–308. doi:10.1007/s007020100006
51. Djaldetti R, Ziv I, Melamed E. The mystery of motor asymmetry in Parkin-
son’s disease. Lancet Neurol (2006) 5(9):796–802. doi:10.1016/S1474-4422(06)
70549-X
52. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neuro-
surg Psychiatry (2008) 79(4):368–76. doi:10.1136/jnnp.2007.131045
53. Perez XA, Parameswaran N, Huang LZ, O’Leary KT, Quik M. Pre-synaptic
dopaminergic compensation after moderate nigrostriatal damage in non-
human primates. J Neurochem (2008) 105(5):1861–72. doi:10.1111/j.1471-
4159.2008.05268.x
54. de la Fuente-Fernandez R, Schulzer M, Kuramoto L, Cragg J, Ramachandi-
ran N, Au WL, et al. Age-specific progression of nigrostriatal dysfunction in
Parkinson’s disease. Ann Neurol (2011) 69(5):803–10. doi:10.1002/ana.22284
55. Agid Y. Parkinson’s disease: pathophysiology. Lancet (1991) 337(8753):1321–4.
doi:10.1016/0140-6736(91)92989-F
56. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain
dopamine and the syndromes of Parkinson and Huntington. Clinical, mor-
phological and neurochemical correlations. J Neurol Sci (1973) 20(4):415–55.
doi:10.1016/0022-510X(73)90175-5
57. Obeso JA, Rodriguez-Oroz MC, Lanciego JL, Rodriguez Diaz M. How does
Parkinson’s disease begin? The role of compensatory mechanisms. Trends Neu-
rosci (2004) 27(3):125–7. doi:10.1016/j.tins.2003.12.006
58. Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early
Parkinson disease. Neurology (2009) 72(7 Suppl):S32–8. doi:10.1212/WNL.
0b013e318198e0e9
59. Greenbaum L, Lorberboym M, Melamed E, Rigbi A, Barhum Y, Kohn Y, et al.
Perspective: identification of genetic variants associated with dopaminergic
compensatory mechanisms in early Parkinson’s disease. Front Neurosci (2013)
7:52. doi:10.3389/fnins.2013.00052
60. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compen-
sations after lesions of central dopaminergic neurons: some clinical and basic
implications. Trends Neurosci (1990) 13(7):290–6. doi:10.1016/0166-2236(90)
90112-N
61. Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM. Neurochemical com-
pensation after nigrostriatal bundle injury in an animal model of preclinical
parkinsonism. Arch Neurol (1984) 41(8):856–61. doi:10.1001/archneur.1984.
04050190062015
62. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo
positron emission tomographic evidence for compensatory changes in presy-
naptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol (2000)
47(4):493–503. doi:10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.3.
CO;2-W
63. Creese I, Burt DR, Snyder SH. Dopamine receptor binding enhance-
ment accompanies lesion-induced behavioral supersensitivity. Science (1977)
197(4303):596–8. doi:10.1126/science.877576
64. Falardeau P, Bedard PJ, Di Paolo T. Relation between brain dopamine loss
and D2 dopamine receptor density in MPTP monkeys. Neurosci Lett (1988)
86(2):225–9. doi:10.1016/0304-3940(88)90575-7
www.frontiersin.org February 2015 | Volume 6 | Article 27 | 7
Greenbaum and Lerer Antipsychotic-induced movement disorders and PD genetics
65. Todd RD, Carl J, Harmon S, O’Malley KL, Perlmutter JS. Dynamic changes in
striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons.
J Neurosci (1996) 16(23):7776–82.
66. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F. Dopamine transporter
messenger RNA in Parkinson’s disease and control substantia nigra neurons.
Ann Neurol (1994) 35(4):494–8. doi:10.1002/ana.410350421
67. Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl
AJ. Dopamine transporter relation to dopamine turnover in Parkinson’s dis-
ease: a positron emission tomography study. Ann Neurol (2007) 62(5):468–74.
doi:10.1002/ana.21204
68. Porritt MJ, Batchelor PE, Hughes AJ, Kalnins R, Donnan GA, Howells DW.
New dopaminergic neurons in Parkinson’s disease striatum. Lancet (2000)
356(9223):44–5. doi:10.1016/S0140-6736(00)02437-5
69. Huot P, Levesque M, Parent A. The fate of striatal dopaminergic neurons in
Parkinson’s disease and Huntington’s chorea. Brain (2007) 130(Pt 1):222–32.
doi:10.1093/brain/awl332
70. Huot P, Levesque M, Morissette M, Calon F, Dridi M, Di Paolo T, et al. L-
DOPA treatment abolishes the numerical increase in striatal dopaminergic
neurons in parkinsonian monkeys. J Chem Neuroanat (2008) 35(1):77–84.
doi:10.1016/j.jchemneu.2007.06.004
71. Black KJ, Koller JM, Campbell MC, Gusnard DA, Bandak SI. Quantification of
indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkin-
son disease. J Neurosci (2010) 30(48):16284–92. doi:10.1523/JNEUROSCI.
2590-10.2010
72. Palmer SJ, Ng B, Abugharbieh R, Eigenraam L, McKeown MJ. Motor reserve
and novel area recruitment: amplitude and spatial characteristics of com-
pensation in Parkinson’s disease. Eur J Neurosci (2009) 29(11):2187–96.
doi:10.1111/j.1460-9568.2009.06753.x
73. Yu H, Sternad D, Corcos DM, Vaillancourt DE. Role of hyperactive cerebellum
and motor cortex in Parkinson’s disease. Neuroimage (2007) 35(1):222–33.
doi:10.1016/j.neuroimage.2006.11.047
74. Appel-Cresswell S, de la Fuente-Fernandez R, Galley S, McKeown MJ. Imaging
of compensatory mechanisms in Parkinson’s disease. Curr Opin Neurol (2010)
23(4):407–12. doi:10.1097/WCO.0b013e32833b6019
75. Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, et al.
Genomewide association study for onset age in Parkinson disease. BMC Med
Genet (2009) 10:98. doi:10.1186/1471-2350-10-98
76. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distrib-
ution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology
(1999) 52(6):1214–20. doi:10.1212/WNL.52.6.1214
77. Schrag A, Schott JM. Epidemiological, clinical, and genetic characteristics
of early-onset parkinsonism. Lancet Neurol (2006) 5(4):355–63. doi:10.1016/
S1474-4422(06)70411-2
78. Greenbaum L, Rigbi A, Lipshtat N, Cilia R, Tesei S, Asselta R, et al. Association
of nicotine dependence susceptibility gene, CHRNA5, with Parkinson’s disease
age at onset: gene and smoking status interaction. Parkinsonism Relat Disord
(2013) 19(1):72–6. doi:10.1016/j.parkreldis.2012.07.007
79. Klebe S, Golmard JL, Nalls MA, Saad M, Singleton AB, Bras JM, et al. The
Val158Met COMT polymorphism is a modifier of the age at onset in Parkin-
son’s disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry (2013)
84(6):666–73. doi:10.1136/jnnp-2012-304475
80. Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premo-
tor) Parkinson’s disease. Parkinsonism Relat Disord (2007) 13(Suppl 3):S425–8.
doi:10.1016/S1353-8020(08)70042-7
81. Varrone A, Halldin C. Molecular imaging of the dopamine transporter. J Nucl
Med (2010) 51(9):1331–4. doi:10.2967/jnumed.109.065656
82. Stokes PR, Shotbolt P, Mehta MA, Turkheimer E, Benecke A, Copeland
C, et al. Nature or nurture? Determining the heritability of human striatal
dopamine function: an [18F]-DOPA PET study. Neuropsychopharmacology
(2013) 38(3):485–91. doi:10.1038/npp.2012.207
83. Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism: an
18F-dopa PET study. Neurology (1993) 43(3 Pt 1):552–6. doi:10.1212/WNL.
43.3_Part_1.552
84. Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, et al.
[123I]FP-CIT SPET imaging in drug-induced parkinsonism. Mov Disord
(2008) 23(13):1825–9. doi:10.1002/mds.22098
85. Tinazzi M, Antonini A, Bovi T, Pasquin I, Steinmayr M, Moretto G, et al. Clin-
ical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced
parkinsonism. J Neurol (2009) 256(6):910–5. doi:10.1007/s00415-009-5039-0
86. Blanchet PJ. Antipsychotic drug-induced movement disorders. Can J Neurol
Sci (2003) 30(Suppl 1):S101–7. doi:10.1017/S0317167100003309
87. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dysk-
inesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology
and mechanisms of induction. Can J Psychiatry (2005) 50(9):541–7.
88. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tar-
dive dyskinesia in outpatients maintained on neuroleptic medications. J Clin
Psychiatry (1993) 54(4):133–9.
89. Remington G. Tardive dyskinesia: eliminated, forgotten,or overshadowed? Curr
Opin Psychiatry (2007) 20(2):131–7. doi:10.1097/YCO.0b013e328017f6b1
90. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin
Psychiatry (2008) 21(2):151–6. doi:10.1097/YCO.0b013e3282f53132
91. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of
the literature. Schizophr Bull (1992) 18(4):701–15. doi:10.1093/schbul/18.4.701
92. Kane JM. Tardive dyskinesia: epidemiological and clinical presentation. In:
Bloom FE, Kupfer DJ, editors. Psychopharmacology: The 4th Generation of
Progress. New York, NY: Raven Press (1995). p. 1485–96.
93. Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects
and tardive dyskinesia. Int Clin Psychopharmacol (1998) 13(Suppl 3):S49–57.
doi:10.1097/00004850-199803003-00009
94. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull
(1997) 23(4):583–609. doi:10.1093/schbul/23.4.583
95. Delfs JM, Ellison GD, Mercugliano M, Chesselet MF. Expression of glutamic
acid decarboxylase mRNA in striatum and pallidum in an animal model of tar-
dive dyskinesia. Exp Neurol (1995) 133(2):175–88. doi:10.1006/exnr.1995.1020
96. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neu-
rochem (1998) 71(3):1002–12. doi:10.1046/j.1471-4159.1998.71031002.x
97. Naidu PS, Singh A, Kulkarni SK. Carvedilol attenuates neuroleptic-induced
orofacial dyskinesia: possible antioxidant mechanisms. Br J Pharmacol (2002)
136(2):193–200. doi:10.1038/sj.bjp.0704717
98. Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive
patients with first-episode psychoses: a systematic review. Psychol Med (2009)
39(7):1065–76. doi:10.1017/S0033291708004716
99. Konig P, Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H. Amantadine
versus biperiden: a double-blind study of treatment efficacy in neuroleptic
extrapyramidal movement disorders. Neuropsychobiology (1996) 33(2):80–4.
doi:10.1159/000119254
100. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psy-
chiatry (2000) 61(Suppl 4):10–4.
101. Whitty PF, Owoeye O, Waddington JL. Neurological signs and involuntary
movements in schizophrenia: intrinsic to and informative on systems pathobi-
ology. Schizophr Bull (2009) 35(2):415–24. doi:10.1093/schbul/sbn126
102. Mercuri NB, Bernardi G. The ‘magic’ of L-DOPA: why is it the gold stan-
dard Parkinson’s disease therapy? Trends Pharmacol Sci (2005) 26(7):341–4.
doi:10.1016/j.tips.2005.05.002
103. Prashanth LK, Fox S, Meissner WG. L-DOPA-induced dyskinesia-clinical
presentation, genetics, and treatment. Int Rev Neurobiol (2011) 98:31–54.
doi:10.1016/B978-0-12-381328-2.00002-X
104. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neu-
rosci (2008) 9(9):665–77. doi:10.1038/nrn2471
105. Del Sorbo F,Albanese A. Levodopa-induced dyskinesias and their management.
J Neurol (2008) 255(Suppl 4):32–41. doi:10.1007/s00415-008-4006-5
106. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year
study of the incidence of dyskinesia in patients with early Parkinson’s disease
who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med
(2000) 342(20):1484–91. doi:10.1056/NEJM200005183422004
107. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of
Parkinson’s disease: non-L-DOPA-responsive problems dominate at 15 years.
Mov Disord (2005) 20(2):190–9. doi:10.1002/mds.20324
108. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced
dyskinesias. Mov Disord (2007) 22(10):1379–89. doi:10.1002/mds.21475
109. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and
motor fluctuations as estimated from the cumulative literature. Mov Disord
(2001) 16(3):448–58. doi:10.1002/mds.1090
Frontiers in Neurology | Movement Disorders February 2015 | Volume 6 | Article 27 | 8
Greenbaum and Lerer Antipsychotic-induced movement disorders and PD genetics
110. Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, et al. Sex dif-
ferences in clinical and genetic determinants of levodopa peak-dose dyskinesias
in Parkinson disease: an exploratory study. Arch Neurol (2005) 62(4):601–5.
doi:10.1001/archneur.62.4.601
111. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of
Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol
(2006) 5(8):677–87. doi:10.1016/S1474-4422(06)70521-X
112. Fisone G, Bezard E. Molecular mechanisms of L-DOPA-induced dyskinesia. Int
Rev Neurobiol (2011) 98:95–122. doi:10.1016/B978-0-12-381328-2.00004-3
113. Ha AD, Jankovic J. An introduction to dyskinesia – the clinical spectrum. Int
Rev Neurobiol (2011) 98:1–29. doi:10.1016/B978-0-12-381328-2.00001-8
114. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol (2000)
47(4 Suppl 1):S2–9.
115. Fabbrini G, Defazio G, Colosimo C, Suppa A, Bloise M, Berardelli A. Onset and
spread of dyskinesias and motor symptoms in Parkinson’s disease. Mov Disord
(2009) 24(14):2091–6. doi:10.1002/mds.22703
116. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clini-
cal manifestations. Mov Disord (2005) 20(Suppl 11):S11–6. doi:10.1002/mds.
20458
117. Tambasco N, Simoni S, Marsili E, Sacchini E, Murasecco D, Cardaioli G, et al.
Clinical aspects and management of levodopa-induced dyskinesia. Parkinsons
Dis (2012) 2012:745947. doi:10.1155/2012/745947
118. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-
induced dyskinesias and response fluctuations in young-onset Parkinson’s dis-
ease. Neurology (1991) 41(2 Pt 1):202–5. doi:10.1212/WNL.41.2_Part_1.202
119. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease.
A community-based study. Brain (2000) 123(Pt 11):2297–305.
120. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of
tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry (1998)
155(11):1521–8. doi:10.1176/ajp.155.11.1521
121. Yassa R, Nastase C, Dupont D, Thibeau M. Tardive dyskinesia in elderly
psychiatric patients: a 5-year study. Am J Psychiatry (1992) 149(9):1206–11.
doi:10.1176/ajp.149.9.1206
122. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic
neurotransmission and oxidative stress associated with tardive dyskinesia. Am
J Psychiatry (1998) 155(9):1207–13. doi:10.1176/ajp.155.9.1207
123. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced
dyskinesias in parkinsonian monkeys. Mov Disord (1998) 13(5):798–802.
doi:10.1002/mds.870130507
124. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase
TN, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an
acute double-blind placebo-controlled study. Mov Disord (2001) 16(3):515–20.
doi:10.1002/mds.1112
125. Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of
amantadine hydrochloride and neuroleptics in the treatment of tardive dysk-
inesia. J Clin Psychopharmacol (1997) 17(2):88–91. doi:10.1097/00004714-
199704000-00004
126. Li CT, Chou KH, Su TP, Huang CC, Chen MH, Bai YM, et al. Gray mat-
ter abnormalities in schizophrenia patients with tardive dyskinesia: a mag-
netic resonance imaging voxel-based morphometry study. PLoS One (2013)
8(8):e71034. doi:10.1371/journal.pone.0071034
127. Cerasa A, Messina D, Pugliese P, Morelli M, Lanza P, Salsone M, et al. Increased
prefrontal volume in PD with levodopa-induced dyskinesias: a voxel-based
morphometry study. Mov Disord (2011) 26(5):807–12. doi:10.1002/mds.23660
128. Rascol O, Fabre N. Dyskinesia: L-DOPA-induced and tardive dyskinesia. Clin
Neuropharmacol (2001) 24(6):313–23. doi:10.1097/00002826-200111000-
00002
129. Cerasa A, Fasano A, Morgante F, Koch G, Quattrone A. Maladaptive plasticity
in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights
on the effects of dopamine receptor pharmacology. Front Neurol (2014) 5:49.
doi:10.3389/fneur.2014.00049
130. Greenbaum L, Goldwurm S, Zozulinsky P, Lifschytz T, Cohen OS, Yahalom G,
et al. Do tardive dyskinesia and L-DOPA induced dyskinesia share common
genetic risk factors? An exploratory study. J Mol Neurosci (2013) 51(2):380–8.
doi:10.1007/s12031-013-0020-x
131. Paus S, Gadow F, Knapp M, Klein C, Klockgether T, Wullner U. Motor compli-
cations in patients form the German competence network on Parkinson’s dis-
ease and the DRD3 Ser9Gly polymorphism. Mov Disord (2009) 24(7):1080–4.
doi:10.1002/mds.22508
132. Foltynie T, Cheeran B, Williams-Gray CH, Edwards MJ, Schneider SA,
Weinberger D, et al. BDNF val66met influences time to onset of levodopa
induced dyskinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry (2009)
80(2):141–4. doi:10.1136/jnnp.2008.154294
133. Molchadski I, Korczyn AD, Cohen OS, Katzav A, Nitzan Z, Chapman J, et al. The
role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia. Acta
Neurol Scand (2011) 123(2):117–21. doi:10.1111/j.1600-0404.2010.01352.x
134. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic
drug response. Am J Psychiatry (2004) 161(5):780–96. doi:10.1176/appi.ajp.
161.5.780
135. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for wide-
spread clinical use? Schizophr Bull (2008) 34(6):1130–44. doi:10.1093/schbul/
sbn114
136. Ala-Korpela M, Kangas AJ, Inouye M. Genome-wide association studies
and systems biology: together at last. Trends Genet (2011) 27(12):493–8.
doi:10.1016/j.tig.2011.09.002
137. Eleftherohorinou H, Wright V, Hoggart C, Hartikainen AL, Jarvelin MR, Bald-
ing D, et al. Pathway analysis of GWAS provides new insights into genetic
susceptibility to 3 inflammatory diseases. PLoS One (2009) 4(11):e8068.
doi:10.1371/journal.pone.0008068
138. Chahine LM, Stern MB, Chen-Plotkin A. Blood-based biomarkers for Parkin-
son’s disease. Parkinsonism Relat Disord (2014) 20(Suppl 1):S99–103. doi:10.
1016/S1353-8020(13)70025-7
139. Ammal Kaidery N, Tarannum S, Thomas B. Epigenetic landscape of Parkin-
son’s disease: emerging role in disease mechanisms and therapeutic modalities.
Neurotherapeutics (2013) 10(4):698–708. doi:10.1007/s13311-013-0211-8
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 13 February 2014; accepted: 30 January 2015; published online: 20 February
2015.
Citation: Greenbaum L and Lerer B (2015) Pharmacogenetics of antipsychotic-induced
movement disorders as a resource for better understanding Parkinson’s disease modifier
genes. Front. Neurol. 6:27. doi: 10.3389/fneur.2015.00027
This article was submitted to Movement Disorders, a section of the journal Frontiers in
Neurology.
Copyright © 2015 Greenbaum and Lerer . This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org February 2015 | Volume 6 | Article 27 | 9
